What are the current screening guidelines for sexually transmitted infections, including which populations should be screened, which infections to test for, recommended specimen types and testing locations, and the source of these guidelines?

STI Screening Guidelines: Who, What, Where, and From Whom

All sexually active women aged 24 years and younger should be screened annually for chlamydia and gonorrhea, with additional screening for women 25 years and older who have risk factors; these recommendations come primarily from the U.S. Preventive Services Task Force (USPSTF), Centers for Disease Control and Prevention (CDC), and American Academy of Pediatrics (AAP). 1, 2

Primary Guideline Sources

The major authoritative bodies providing STI screening guidelines include:

• U.S. Preventive Services Task Force (USPSTF) - provides evidence-based recommendations for general populations
• Centers for Disease Control and Prevention (CDC) - issues comprehensive STI treatment and screening guidelines
• American Academy of Pediatrics (AAP) - focuses on adolescent and young adult populations
• American College of Obstetricians and Gynecologists (ACOG) - addresses pregnant women specifically

These organizations show strong consensus on core recommendations, though the AAP guidelines from 2014 provide the most detailed adolescent-specific guidance 1.

Population-Specific Screening Recommendations

Sexually Active Women (Non-Pregnant)

Age-Based Universal Screening:

• Chlamydia and gonorrhea: Screen ALL sexually active women ≤24 years annually 1, 2
• Women ≥25 years: Screen only if risk factors present 2

Risk-Based Screening (any age): Screen for chlamydia, gonorrhea, HIV, and syphilis if any of these risk factors exist 2:

• Multiple current sexual partners
• New sexual partner
• Inconsistent condom use
• Sex while under influence of alcohol or drugs
• Sex in exchange for money or drugs
• History of previous STIs
• Partner with known STI

Important caveat: The USPSTF explicitly recommends AGAINST routine screening in women ≥25 years without risk factors, as the low prevalence makes routine screening inefficient 2.

Pregnant Women

Universal Screening (ALL pregnant women): 2

• Syphilis: At first prenatal visit, third trimester, and at delivery
• HIV: At first prenatal visit
• Hepatitis B: At first prenatal visit

Risk-Based Screening in Pregnancy:

• Chlamydia and gonorrhea: Screen if ≤24 years OR if older with risk factors 2
• Retest in third trimester if positive in first trimester 3

Men Who Have Sex with Men (MSM)

This population requires the most intensive screening due to highest risk burden 1:

Annual screening at minimum:

• Urethral gonorrhea and chlamydia (if insertive intercourse)
• Rectal gonorrhea and chlamydia (if receptive anal intercourse)
• Pharyngeal gonorrhea and chlamydia (if receptive oral sex)
• Syphilis serology
• HIV

Every 3-6 months if high-risk (multiple/anonymous partners, drug use during sex, methamphetamine use): 1, 3

• All above tests at all anatomic sites of exposure

Critical point: Specimen collection must be guided by sexual behavior history - you cannot rely on urethral specimens alone. Ask specifically about oral and anal exposures and test those sites 1.

Heterosexual Men

The evidence here is notably weaker 2:

• USPSTF states insufficient evidence to recommend routine screening for chlamydia or gonorrhea in men 2
• However, consider annual screening in high-prevalence settings: correctional facilities, STD clinics, adolescent clinics, areas with high community prevalence 1
• Screen for HIV and syphilis if engaging in high-risk behaviors 2

Adolescents and Young Adults

Key principle: Sexual history should guide specimen collection sites 1:

All sexually active adolescents:

• Females ≤25 years: Annual chlamydia and gonorrhea screening 1
• Males: Consider screening based on local prevalence and individual risk factors 1

Special populations with higher burden:

• Youth of color
• Sexual minority youth
• Transgender youth (though data limited) 1

Screening should begin: No specific age recommended, but consider starting at age 12 if sexually active, as some adolescents initiate intercourse this early 2.

What Infections to Test For

Core Bacterial STIs (Most Important for Screening)

Chlamydia trachomatis:

• Most common reportable STI
• Often asymptomatic but causes pelvic inflammatory disease, infertility, ectopic pregnancy in women 1
• Screen using nucleic acid amplification tests (NAATs) - most sensitive 1

Neisseria gonorrhoeae:

• Second most common bacterial STI
• Similar complications to chlamydia
• Increasing antibiotic resistance makes detection critical 1
• Screen using NAATs 1

Syphilis:

• Screen MSM annually or every 3-6 months if high-risk 1, 3
• Screen all pregnant women 2
• Screen heterosexuals only if risk factors present 1
• Use serology testing 1

HIV:

• Screen all persons aged 15-65 years at least once regardless of risk 2
• Screen younger/older patients if risk factors present
• More frequent screening for MSM and others at ongoing risk 3

Infections NOT Routinely Screened

Trichomoniasis:

• Do NOT routinely screen asymptomatic adolescents 1
• Consider screening only in high-risk females: multiple partners, history of STIs, sex work, injection drug use 1
• If diagnosed, consider rescreening at 3 months 1

Herpes Simplex Virus (HSV):

• Do NOT screen asymptomatic persons 2
• No benefit demonstrated from screening

Human Papillomavirus (HPV):

• Not used as primary screening except in cervical cancer screening context (age ≥30 years with cytology) 2
• Do not screen for subclinical infection 2

Where to Test: Specimen Types and Collection Sites

Anatomic Site-Based Testing

The critical principle: Test the sites of sexual exposure 1:

For women:

• Vaginal swabs (self-collected or clinician-collected) for chlamydia/gonorrhea
• Cervical specimens acceptable but vaginal preferred for patient comfort
• Pharyngeal swabs if receptive oral sex
• Rectal swabs if receptive anal sex

For men:

• First-catch urine for urethral chlamydia/gonorrhea
• Pharyngeal swabs if receptive oral sex
• Rectal swabs if receptive anal sex
• Urethral swabs if symptomatic

For MSM specifically:

• Must obtain specimens from ALL sites of exposure (pharynx, rectum, urethra) based on sexual practices 1
• Cannot rely on urine alone - will miss most infections

Testing Methodology

Nucleic Acid Amplification Tests (NAATs):

• Preferred method for chlamydia and gonorrhea 1
• Can use non-invasive specimens (urine, self-collected vaginal swabs)
• Most sensitive and specific

Serology:

• Required for syphilis and HIV screening 1

Rescreening After Treatment

This is frequently overlooked but critical 1:

Chlamydia or gonorrhea:

• Rescreen ALL patients 3 months after treatment, regardless of whether partners were treated 1
• If 3-month retest not possible, retest at next healthcare visit within 12 months 1
• Rationale: High reinfection rates, not treatment failure

Trichomoniasis:

• Consider rescreening females at 3 months 1

Special Considerations and Common Pitfalls

Sexual History Taking

Must ask about:

• Same-sex AND opposite-sex partners, regardless of stated sexual orientation 1
• Specific sexual practices: vaginal, oral, anal (insertive vs receptive) 1
• Number of partners, new partners
• Condom use consistency
• Substance use during sex

Cultural sensitivity required: Consider ethnic, racial, cultural factors and sexual minority status 1

High-Prevalence Settings

Consider more intensive screening in 1:

• Correctional facilities (universal screening of adolescent females)
• STD clinics
• Adolescent clinics
• National job training programs
• Communities with high local prevalence (consult local health department data)

Age Considerations

When to stop screening:

• No specific upper age limit if risk continues 2
• Reasonable to stop routine screening at menopause or age 55 in women at risk only due to demographics (not behavior) 2
• Clinical implications differ in post-reproductive age (infertility no longer relevant)

Opt-Out Screening

Some guidelines suggest opt-out screening (patient must decline rather than consent) in high-prevalence populations, potentially as frequently as every 3 months 4, 5.

Partner Management

When STI diagnosed 1:

• Offer expedited partner therapy where legally permissible
• Emphasize partner treatment to prevent reinfection
• This is why rescreening at 3 months is essential

Limitations and Gaps

Insufficient evidence exists for:

• Routine screening of heterosexual men for chlamydia/gonorrhea 2
• Optimal screening intervals beyond the recommendations above
• Transgender youth (though older transgender populations at high risk) 1

The evidence consistently shows that untreated asymptomatic infections lead to serious complications including pelvic inflammatory disease, infertility, ectopic pregnancy, and increased HIV transmission risk 1. The screening recommendations prioritize preventing these morbidities, particularly in young women who bear the greatest burden of reproductive complications.